title: High-resolution manometric evaluation of the effects of cisapride and metoclopramide hydrochloride administered orally on lower esophageal sphincter pressure in awake dogs.
abstract: OBJECTIVE
  To evaluate the effects of cisapride and metoclopramide hydrochloride administered orally on the lower esophageal sphincter (LES) resting pressure in awake healthy dogs.
  
  
  METHODS
  6 adult Beagles.
  
  
  METHODS
  Each dog was evaluated after administration of a single dose of cisapride (0.5 mg/kg), metoclopramide (0.5 mg/kg), or placebo (empty gelatin-free capsule) in 3 experiments performed at 3-week intervals. To measure LES pressure, a high-resolution manometry catheter equipped with 40 pressure sensors spaced 10 mm apart was used. For each experiment, LES pressure was recorded during a 20-minute period with a virtual electronic sleeve emulation before treatment (baseline) and at 1, 4, and 7 hours after drug or placebo administration. A linear mixed-effects model was used to test whether the 3 treatments affected LES pressure differently.
  
  
  RESULTS
  In the cisapride, metoclopramide, and placebo experiments, median baseline LES pressures were 29.1, 30.5, and 29.0 mm Hg, respectively. For the cisapride, metoclopramide, and placebo treatments, median LES pressures at 1 hour after administration were 44.4, 37.8, and 36.6 mm Hg, respectively; median LES pressures at 4 hours after administration were 50.7, 30.6, and 31.1 mm Hg, respectively; and median LES pressures at 7 hours after administration were 44.3, 28.5, and 33.3 mm Hg, respectively. The LES pressures differed significantly only between the placebo and cisapride treatments.
  
  
  CONCLUSIONS
  Results suggested that orally administered cisapride may be of benefit in canine patients for which an increase in LES pressure is desirable, whereas orally administered metoclopramide did not affect LES resting pressures in dogs.
authors.affiliation: Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Kempf
authors.forename: Fraser
authors.initials: F
authors.lastname: Lewis
authors.forename: Claudia E
authors.initials: CE
authors.lastname: Reusch
authors.forename: Peter H
authors.initials: PH
authors.lastname: Kook
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage / Q000494:pharmacology; D020117:Cisapride / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D049630:Esophageal Sphincter, Lower / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008365:Manometry / Q000379:methods / Q000662:veterinary*; D008787:Metoclopramide / Q000008:administration & dosage / Q000494:pharmacology*; D011312:Pressure
chemical_list: D000932:Antiemetics; D005765:Gastrointestinal Agents; D008787:Metoclopramide; D020117:Cisapride